

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

AF	PLICATION NO.	FILING DATE	F	IRST NAMED INVENTOR	ATTORN	NEY DOCKET NO.
•	09/402	,634 03/2	:7/00 R(ONIKER		CU-2019-RJ
_		·		HM12/0605	EXAMINER	
	THOMAS F PETERSON LADAS & PARRY			THE STANCES	JAGOE	. <u> </u>
		JTH MICHIGA	hi Atimania	•	ART UNIT	PAPER NUMBER
	CHICAG	D IL 60604	N HAFINTE		1614	8
	•				DATE MAILED:	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

06/05/01

BEST AVAILABLE COPY

<u> </u>									
. 20	Application No.		Applicant(s)						
Office Action Summary	09/402,634		RONIKER ET AL.						
	Examiner		Art Unit						
	Donna A. Jagoe		1614						
The MAILING DATE of this communication appe Peri d for Reply	ears on the cover shee	et with the co	respondence ad	ldress					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status									
1) Responsive to communication(s) filed on	<u> </u>								
2a) This action is FINAL . 2b) Th	is action is non-final.								
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposition of Claims									
4)⊠ Claim(s) <u>1-12</u> is/are pending in the application									
4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.									
6) ☐ Claim(s) is/are rejected.									
7) Claim(s) is/are objected to.									
8)⊠ Claims <u>1-12</u> are subject to restriction and/or e	election requirement.								
Application Papers									
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are objected to by the Examiner.									
11) The proposed drawing correction filed on is: a) approved b) disapproved.									
12) The oath or declaration is objected to by the Examiner.									
Pri rity under 35 U.S.C. \$ 119									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. \$ 119(a)-(d) or (f).									
a) ☐ All b) ☐ Some * c) ☐ None of:									
1. Certified copies of the priority documents have been received.									
2. Certified copies of the priority documents have been received in Application No									
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).									
Attachment(s)									
15) Notice of References Cited (PTO-892)	18) 🔲 Int	terview Summan	/ (PTO-413) Paper I	No(s)					
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) 🔲 No	otice of Informal	Patent Application (
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	20) [_] Oti	her: .							

Application/Control Number: 09/402,634

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9, drawn to a method of preventing an inflammation related cardiovascular disorder with meloxicam, nimesulide, MK-966, L-783003, T-614, D-1367, L-748731, CT3, CGP-28238, BF-389, GR-253035, (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-3, 6-dioxo-9H-purinyl-8-yl)cinamic acid or L-745337and a compound of formula I

Group II, claim(s) 10-12, drawn to a method of preventing an inflammation related cardiovascular disorder with a compound of formula IIThe inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the compounds of group I and II are separate and distinct and each require a separate search.

Because these inventions are distinct/unrelated for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Moreover, because a search of each distinct/unrelated invention would not be coextensive with the other(s), and because each invention will require its own separate patentability analysis, an examination and search of multiple inventions in a single application would constitute a serious undue burden on the examiner.

Application/Control Number: 09/402,634

Art Unit: 1614

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- (A) Cardiovascular disorders of claims 2, 3, 4, 9 and 12;
- (B) compounds of claim 5 and 8;
- (C) A substituents of compound I of claims 5, 6, 7,
- (D) R4 substituents of compound II of claims 10 and 11.

Applicant is required, in reply to this action, to elect a single species of each to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: 1-2 and 5-12.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna A. Jagoe whose telephone number is (703) 306-5826. The examiner can normally be reached on 6:30 A.M. - 3 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Cintins can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3230 for regular communications and (703) 308-7921 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0193.

dj May 31, 2001. PRIMARY EXAMINER
GROUP 300